- Home
- /
- Growth Factor / Endocrine Research
- /
- CJC-1295 (No DAC) / Ipamorelin 5/5mg
SKU
AZ-CJCIPA-55
CJC-1295 (No DAC) / Ipamorelin 5/5mg
Pricing
In stock
Fulfillment Timing Based on Inventory and Account Status.
CJC-1295 (No DAC) / Ipamorelin 5/5mg
HPLC Certified
CAS #
863288-34-0 / 170851-70-4
M.W.
3367.9 / 711.85
Formula
Multi-Component Peptide Blend
- PURITY
- ≥99%
RUO
- (Research Use Only)
Specs:
- Amount: 5mg/5mg | Format: Lyophilized Powder | Container: 3mL Vial | Storage: 2-8°C | Type: Single Peptide | Research Alias: CJC/IPA Blend | Blend Breakdown: CJC-1295 No DAC 5mg + Ipamorelin 5mg | Research Category: Peptide Receptor Pathway Research
CJC-1295 Ipamorelin Blend | Dual Growth Hormone Secretagogues | AZOTH
What Is the CJC-1295 Ipamorelin Blend?
The cjc 1295 ipamorelin blend pairs two synthetic peptides acting on one endocrine axis through two receptors. AZOTH supplies this synthetic peptide blend as a single lyophilized vial, 5mg of each peptide, 10mg total.
CJC-1295 (no DAC) is also catalogued as Mod GRF 1-29. It is a shortened, stabilized analog of growth hormone releasing hormone.
Ipamorelin is a pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Raun and colleagues characterized it in 1998 as the first selective growth hormone secretagogue. It does not stimulate the releasing-hormone arm at all.
Researchers pair these peptides because each reaches the pituitary gland by a different route. Studying them together isolates questions neither answers alone.
These peptides are restricted to laboratory research. Not for human consumption.
How CJC-1295 No DAC Differs From the DAC Variant
CJC-1295 no DAC omits the Drug Affinity Complex binding the parent molecule to serum albumin. Removing it shortens circulating time.
The DAC version carries a half life measured in days. CJC-1295 no DAC has a short half life closer to thirty minutes.
A short half life produces a discrete pulse, letting researchers watch pulsatility instead of a flat baseline.
Alba and colleagues documented the prolonged stimulation profile of the albumin-bound form in knockout mice, where 24-hour intervals normalized body growth.
How the Two Peptides Work Through Complementary Pathways
The cjc 1295 ipamorelin combination is studied because both peptides converge on growth hormone output by complementary pathways.
CJC-1295 and the GHRH Receptor
CJC-1295 binds the ghrh receptor on anterior pituitary somatotrophs. Receptor occupancy raises intracellular cAMP and activates protein kinase A.
That cascade drives transcription and synthesis. CJC-1295 increases how much hormone the cell has available to release.
The ghrh receptor pathway is the same one the body uses for natural growth hormone production, which is why CJC-1295 preserves pulsatility rather than overriding it.
In clinical endocrinology, Ionescu and Frohman reported that pulsatile secretion persisted during continuous stimulation by CJC-1295, a result that still anchors how researchers model cjc 1295 no dac.
Ipamorelin and the Ghrelin Receptor
Ipamorelin acts at GHS-R1a, the receptor for ghrelin. This is a Gq/11-coupled receptor, so signaling runs through calcium mobilization rather than cAMP.
By mimicking ghrelin at its native receptor, ipamorelin acts on secretory capacity. It changes how readily stored hormone leaves the cell.
Kojima and colleagues identified ghrelin in 1999 as the endogenous ligand for these receptors.
Ipamorelin has a short half life of roughly two hours, longer than CJC-1295 but still transient.
Why CJC-1295 Ipamorelin Is Studied as a Pair
Because the ghrh receptor pathway governs synthesis and ghrelin receptors govern release, the cjc 1295 ipamorelin pairing separates two otherwise confounded variables.
Category literature describes a three to five fold increase in output when the peptides are combined versus either alone. Those figures come from vendor summaries, not trials.
Reports on cjc 1295 no dac describe increases in growth hormone levels from 200 to 1000 percent above baseline. Ranges that wide reflect differing models and assays.
Treat any claim that these peptides increase growth hormone levels by a stated multiple as provisional. Nothing here promises that the compound will increase growth hormone levels in any system.
High Selectivity and the Cortisol and Prolactin Question
Ipamorelin drew attention for its high selectivity. Raun and colleagues found it did not raise ACTH or cortisol beyond what growth hormone releasing hormone stimulation produced.
Prolactin, FSH, LH, and TSH were unchanged. That profile separates it from earlier peptides such as GHRP-6 and GHRP-2, which do elevate cortisol.
For researchers isolating growth hormone effects, a growth hormone secretagogue that leaves cortisol and prolactin alone is methodologically useful.
How CJC-1295 Ipamorelin Compares to Other Peptides in This Class
Sermorelin, Tesamorelin, and CJC-1295 all stimulate GHRH receptors. Hexarelin, GHRP-2, and GHRP-6 stimulate ghrelin receptors instead.
What distinguishes the cjc 1295 ipamorelin blend from other peptides is selectivity on the ghrelin side combined with a clean pulse on the releasing side.
Researchers comparing peptides in this class hold the growth hormone releasing arm constant and vary the secretagogue. CJC-1295 and Ipamorelin stimulate one axis at two receptors, which is the point of the combination.
Product Specifications
| Component | CAS Number | Molecular Formula | Molecular Weight | Purity |
| CJC-1295 (no DAC) 5mg | 863288-34-0 | C152H252N44O42 | 3367.95 g/mol | 99%+ |
| Ipamorelin 5mg | 170851-70-4 | C38H49N9O5 | 711.87 g/mol | 99%+ |
Total CJC-1295 Ipamorelin blend content: 10mg. Format: lyophilized powder. Made in USA.
Buy CJC-1295 Ipamorelin Blend for These Research Applications
Pituitary Signaling and Growth Hormone Pulsatility
Mapping how the CJC-1295 Ipamorelin arms interact when combined is the main application. It gives researchers a two-input system with one output.
Because CJC-1295 no DAC clears quickly, investigators can time sampling to a defined window and observe gh release as a discrete event.
Insulin Like Growth Factor Signaling
Growth hormone acts largely through hepatic insulin like growth factor 1. Teichman and colleagues measured sustained IGF-I elevation alongside growth hormone after cjc 1295 no dac dosing in healthy adults.
That downstream axis is a standard endpoint in studies using this cjc 1295 ipamorelin blend.
Bone Density Research Models
Svensson and colleagues reported increased bone mineral content in adult female rats given ipamorelin by continuous subcutaneous injection.
Andersen and colleagues found ipamorelin counteracted glucocorticoid-induced loss of bone formation in adult rats.
Body Composition and Lean Muscle Mass Research
Body composition is a recurring endpoint across the animal model literature on secretagogue peptides. Alba and colleagues tracked whole-body composition and growth in knockout mice.
Lean muscle mass, body fat mass, and their ratio are measured in these preclinical models as research categories, not expected outcomes.
Muscle growth and lean muscle growth endpoints in rodents reflect protein synthesis driven by growth hormone. Whether they translate elsewhere is unresolved.
Investigators studying lean muscle mass pair the body composition assay with an IGF-I readout.
Metabolism and Fat Loss Research Categories
Fat loss is studied here as lipolysis, the release of stored fat from body tissue by hormone-sensitive lipase under growth hormone influence.
Metabolism endpoints include substrate use, glucose handling, and adipose distribution across the body. Fat loss in rodents establishes nothing about other species.
Adeghate and Ponery examined ipamorelin-evoked insulin release from pancreatic tissue of normal and diabetic rats, a rare direct metabolism readout for these peptides.
Food intake and appetite are confounds, since ghrelin receptors regulate feeding alongside gh release.
Gastrointestinal Motility Research
Beck and colleagues ran a randomized proof-of-concept study of ipamorelin for postoperative ileus in bowel resection patients.
That trial is one of the only controlled human datasets on these peptides, and it addressed motility, not body composition.
Receptor Downregulation and Exposure Interval Research
Continuous occupancy can produce receptor downregulation. How the body adjusts is an open question for every growth hormone secretagogue.
Alba and colleagues found the same dose was less effective at 48 and 72 hour intervals than at 24 hours, which speaks directly to exposure timing.
Nutritional state is a known confound. Growth hormone secretion varies with feeding, so protocols log time since last meal and sample on an empty stomach.
Proper nutrition records belong in the protocol file, since a fed and unfed animal are not comparable subjects.
Research Summary: What the Preclinical Literature Shows
| Research Area | Model | Reported Finding |
| Selectivity | Rat and porcine pituitary | Growth hormone release without ACTH, cortisol, or prolactin rise |
| Bone mineral content | Adult female rats | Increased tibial bone mineral content over 12 weeks |
| Glucocorticoid bone loss | Adult rats | Periosteal bone formation rate preserved |
| Pancreatic insulin release | Normal and diabetic rats | Ipamorelin-evoked insulin secretion observed |
| Postoperative ileus | Human bowel resection patients | Randomized proof-of-concept study conducted |
| Growth normalization | GHRH knockout mice | Body growth and composition normalized at 24h intervals |
| Pulsatility | Healthy adults | Pulsatile secretion preserved during continuous stimulation |
| IGF-I response | Healthy adults | Prolonged stimulation of growth hormone and IGF-I secretion |
Regulatory Status and the Limits of the Evidence
Neither CJC-1295 nor Ipamorelin is FDA approved for any use. No approved product contains this combination, and no synthetic growth hormone equivalence has been established.
The human record is thin. Teichman covered healthy adults over 28 and 49 days; Beck covered surgical patients. Nothing approaches long-term safety data.
Regulatory scrutiny reflects that gap, and peptide therapy clinics operate outside it. Absence of controlled trials is a reason for caution, not an opening.
Why “Peptide Therapy” Language Does Not Apply to This Product
The phrase peptide therapy circulates widely in consumer media and clinic marketing. Peptide therapy does not describe anything AZOTH sells.
Peptide therapy implies a treatment given to patients under medical supervision. These peptides are research chemicals; no medical supervision makes bodily introduction lawful.
Peptide therapy marketing asserts that many patients experience faster recovery, improved body composition, and less water retention. AZOTH makes no such claims.
Peptide therapy copy also asserts that patients notice improved sleep, attributing deeper sleep to combined secretagogue use. No controlled trial on these peptides supports improved sleep as an outcome.
Where peptide therapy describes a treatment protocol, research describes a study design. Different documents, different standards of evidence.
AZOTH publishes what the research shows and stops. No peptide therapy framing. If a claim cannot be traced to a citation, it does not appear here.
Why Researchers Choose AZOTH for CJC-1295 Ipamorelin
Reproducibility depends on knowing what is in the vial. AZOTH manufactures this blend in the United States and documents every lot.
Verified 99%+ purity by HPLC and mass spectrometry
Peptides manufactured in the USA under controlled protocols
Both peptides third-party tested for identity, purity, and content
Peptides supplied as lyophilized powder for shelf stability
Certificate of Analysis available for each batch
Batch-matched COA corresponding to the vial received
Researchers and science-focused customers get defined starting peptides, not an unverified input.
Storage, Handling, and Reconstitution With Bacteriostatic Water
Store the sealed CJC-1295 Ipamorelin vial at 2 to 8 degrees Celsius, away from light and moisture. Lyophilized peptides stay stable up to 24 months.
For longer holds, store at minus 20 degrees Celsius and avoid freeze-thaw cycles.
To reconstitute, wipe the stopper with an alcohol swab, then run bacteriostatic water slowly down the vial wall, not directly onto the powder.
Do not shake. Gently swirl until dissolved. Agitation shears peptides and reduces measurable content.
Record the volume of bacteriostatic water added so concentration is documented.
Keep the reconstituted solution refrigerated and shielded from light. Bacteriostatic water is standard because its preservative supports multi-draw handling.
Laboratory Research Use Only
CJC-1295 and Ipamorelin sold by AZOTH are supplied for in vitro and laboratory research use only.
These peptides are not approved by the Food and Drug Administration for human consumption, medical use, diagnostic procedures, or veterinary use.
They have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or condition.
Bodily introduction into humans or animals is strictly prohibited by law. No clinical setting changes that restriction.
AZOTH provides no dosing guidance or administration protocols. Route of administration appears above only in descriptions of cited studies.
All purchasers must be qualified researchers or laboratory professionals. By purchasing, you confirm you understand your jurisdiction’s regulations and will use these peptides only in a qualified research setting.
| Research Findings | Journal | Data | Source Link |
| 1. Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” | Eur. J. Endocrinol. | 1998; 139(5): 552-561. | https://pubmed.ncbi.nlm.nih.gov/9849822/ |
| 2. Andersen NB, et al. “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.” | Growth Horm. IGF Res. | 2001; 11(5): 266-272. | https://pubmed.ncbi.nlm.nih.gov/11735244/ |
| 3. Svensson J, et al. “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.” | J. Endocrinol. | 2000; 165(3): 569-577. | https://pubmed.ncbi.nlm.nih.gov/10828840/ |
| 4. Adeghate E, Ponery AS. “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats.” | Neuro Endocrinol. Lett. | 2004; 25(6): 403-406. | https://pubmed.ncbi.nlm.nih.gov/15665799/ |
| 5. Beck DE, et al. “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” | Int. J. Colorectal Dis. | 2014; 29(12): 1527-1534. | https://pubmed.ncbi.nlm.nih.gov/25331030/ |
| 6. Alba M, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” | Am. J. Physiol. Endocrinol. Metab. | 2006; 291(6): E1290-E1294. | https://pubmed.ncbi.nlm.nih.gov/16822960/ |
| 7. Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” | J. Clin. Endocrinol. Metab. | 2006; 91(12): 4792-4797. | https://pubmed.ncbi.nlm.nih.gov/17018654/ |
| 8. Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” | J. Clin. Endocrinol. Metab. | 2006; 91(3): 799-805. | https://pubmed.ncbi.nlm.nih.gov/16352683/ |
| 9. Kojima M, et al. “Ghrelin is a growth-hormone-releasing acylated peptide from stomach.” | Nature | 1999; 402(6762): 656-660. | https://pubmed.ncbi.nlm.nih.gov/10604470/ |
Featured Research Compounds
Research use only
All AZOTH products are intended solely for laboratory research, analytical, and scientific use. Products are not for human consumption, human use, veterinary use, diagnostic use, therapeutic use, or administration of any kind.